Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Jason R. Westin, Julio C. Chávez, Stephen J. Schuster, Vladan Vučinić, Patricia Ann Young, Patrick Connor Johnson, Stéfania Bramanti, Alessandro Rambaldi, Javier Briones, Koji Kato, Juan‐Manuel Sancho, Mi Kwon
+11 more Carlos Solano, Shaun A. Fleming, Saurabh Dahiya, Alejandro Martín García-Sancho, Pedro Marques Ramos, David E. Pearson, Salif Diallo, Aiesha Zia, Eduardo Segura, Aisha Masood, Pere Barba
DOI: 10.1016/j.jtct.2025.12.076
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment T-cell and B-cell Immunology

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S48–S49
Publication date
1 February 2026
Language
EN